New anticancer drugs in Europe

Chinese Medical Journal

Volumn 110, Issue 4, 1997, Pages 297-308

  Armand, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CYSTEMUSTINE; DOCETAXEL; EDATREXATE; ENZYME INHIBITOR; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOFOS; GEMCITABINE; IRINOTECAN; LOSOXANTRONE; NAVELBINE; NEW DRUG; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PEMETREXED; PLATINUM DERIVATIVE; RHIZOXIN; SATRAPLATIN; SURAMIN; TELOXANTRONE; TOPOTECAN; UNINDEXED DRUG; VINCA ALKALOID;

CANCER; CLINICAL TRIAL; EUROPE; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; EUROPE; HUMANS; SIGNAL TRANSDUCTION; SURAMIN; TOPOTECAN;

EID: 0030933024     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Mathe G, Misset JL, Triana BK, et al. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourca: an intrapatient escalation scheme. Drugs Exptl Clin Res XVIII 1992; 155.
2. Tisserant A, Plagne R, Roche H, et al. Phase II trial of cystemustine, a new nitrosourea, as second line treatment of malignant gliomas. Proc IVth Intern Congress on Anti-Cancer Chemother Abstr 1993; 239.
3. Twelves CJ, Dobbs NA, Lawrence MA, et al. Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer 1991; 69:726.
4. Villar-Grimalt A, Aranda E, Massuti B, et al. Phase II study with lododoxorubicine in measurable advanced colorectal adenocarcinoma: effective rescue using weekly high-dose 5-fluorouracil (WFU). Tumouri 1994; 80:124.
5. Vasey PA, Bissett D, Strolin-Benedetti M, et al. Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2- methoxy-4-morpholinyl) doxorubicin (FCE 23762). Cancer Res 1995; 55:2090.
6. Groen HJM, Droz JP, Hanauske AR, et al. A feasability study with FCE 23762 every 4 weeks in adults with solid tumours. Proc Am Soc Clin Oncol 1995; 14:468.
7. Skoog LA, Ratain MJ, O'Brien SM, et al. Phase I trial of methoxymorpholinodoxorubicin (FCE 23762, MMD): on a daily X3 schedule. Proc Am Soc Clin Oncol 1995; 14:485.
8. Vanderberg T, ten Bokkel Huinink W, Hedley D, et al. A phase II study of DuP 941 in advanced breast cancer (CA) patients with no prior chemotherapy. Proc Am Soc Clin Oncol 1993; 12:67.
9. Smith L, Goldstein L, Wheeler R, et al. A phase II study of DuP 941 in advanced breast cancer (CA) patients treated with prior chemotherapy. Proc Am Soc Clin Oncol 1993; 12: 67.
10. Shore T, Eisenhauer E, Quirt I, et al. A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG). Ann Oncol 1993; 4:695.
11. Harrison M, Tomlinson D, and Stewart S. Liposomal-encapsulated doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995; 13:914.
12. Shornagel JH, Verweij J, de Mulder PHM, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell cancinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study. J Clin Oncol 1995; 13:1649.
13. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC). A phase II study. Proc Am Soc Clin Oncol 1995; 11:352.
14. Steward WP, Dunlop DJ, Cameron C, et al. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLE). a phase II study. Proc Am Soc Clin Oncol 1995; 14: 352.
15. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine (GEM) versus 5FU as firstline therapy in advanced pancreatic cancer. Proc Am Soc clin Oncol 1995; 14: 199.
16. Carmichael J, Possinger K, Philip P, et al. Difluorodeoxycytidine (gemcitabine): A phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 37.
17. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine in previously platinum treated ovarian cancer (OC). Proc Am Soc Clin Oncol 1993; 12:834.
18. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 1994; 5:283.
19. Cunningham D, Zaleberg J, Francois E, et al. Tomudex (ZD1694) a new thymidilate synthetase inhibitor with good antitumour activity in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1994; 13:199.
20. Smith IE, Spielmann M. Bonneterre J, et al. "Tomudex" (ZD1694), a new thymidilate synthase inhibitor in advanced breast cancer. Ann Oncol 5(suppl5) 1994; 5:132.
21. Pazdur R, Casper ES, Meropol NJ, et al. Phase II trial of "Tomudex" (ZD1694). a thymidialte synthase inhibitor in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994; 13: 207.
22. Touroutoglou N and Pazdur R. Thymidilate synthase inhibitors. Clin Cancer Res 1996; 2:227.
23. Rinaldi DA, Burns HA, Dorr FA, et al. Initial phase 1 evaluation of the novel thymidilate synthetase inhibityor, LY231314, using the modified continual reassesment method for dose escalation. J Clin Oncol 1995; 13:2842.
24. McKeage MJ, Raynaud F, Ward, et al. Phase 1 and pharmacokinetic study of an orally administered platinum (Pt) complex (JM216) using a daily X5 administration schedule. Proc Am Soc clin Oncol 1991; 13:136.
25. Levi F, Perpoint B, Garufi C, et al. Oxaliplating activity against metastatic colorectal cancer: a phase 11 study of 5- day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29:128.
26. Misset JL, Soulie P, Fereres M, et al. High activity of combined oxaliplatin (LOHP) cisplatin (CP) as salvage treatment in pretreated ovarian cancer (OC). Proc Am Soc Clin Oncol 1994; 13:273.
27. Toso C, and Lindley C. Vinorelbine: a novel vinca alkaloid. Am J Health-Syst Pharm 1995; 52:1287.
28. Lucas S, Donehower R, Rowinsky E, et al. Clinical results of a study of the absolute bioavailability (ABA) and pharmacokinetics (PK) of weekly navelbine (NVB) liquid-filled soft gelatin capsules at full therapeutic doses in patients (PTS) with solid tumours. Proc Am Soc Clin Oncol 1992; 11:111.
29. Furnoleau P, Delgado F, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in firstline advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:336.
30. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II sludy. J Clin Oncol 1994; 12:2094.
31. Dieras V, Pierga JY, Extra JM, et al. Phase II study of navelbine (NVB) and fluorouracil (FU) in metastatic breast cancer (MBC) patients using a group sequential design (GSD). Ann Oncl 1992; 3:125.
32. Le Chevallier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360.
33. Gridelli C, Ce Placido S, Pepe R, et al. Phase I study of epirubicin (EDX) plus vinorelbin (VNR) with or whithout G- CSF in advanced non-small cell lung cancer (NSCLC). Eur J Cancer 1993; 29:1729.
34. Morere JF, brunet A, duran A, et al. Ifosfamide (IFX) and vinirelbine (NVB) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13:344.
35. Bisset D, Graham MA, Setanoians A, et al. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 1992; 52: 2894.
36. Kaplan S, Hanauske AR, Pavlidis N, et al. Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1996; 73:403.
37. Sessa C, Zuchetti M, Cerny T, et al. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 1995; 13:200.
38. Kaul S, Igwemezie LN, Stewart DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumours. J Clin Oncol 1995; 13:2835.
39. Miller AA, Hargis JB, Lienbaum RC, et al. Phase I study of topotecan and cisplatin in patients with advanced cancer: a cancer and leukemia group B study. J Clin Oncol 1994; 12:2713.
40. Robert F, Wheeler RH, Molthrop DC, et al. Phase II study of topotecan in advanced head and neck cancer: Identificantion of an active new agent. Proc Am Soc Clin Oncol 1991; 13:905.
41. Eisenhauer EA, Wainman N, Boos G, et al. Phase II trials of topotecan in patients (pts) with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 1994; 13:175.
42. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210.
43. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 146.
44. Rougier PH, Culine S, Bugat R, et al. The European experience with CPT-11 (irinotecan) in the treatment of advanced colorectal cancer. Amsterdam: 6th Conference on DNA Topoisomerases in Therapy, 1995.
45. Chevallier B, Lhomme C, Dieras V, et al. A phase II study of CPT-11 (irinotecan) in chemotherapy naive patients with advanced cabcer of the cervix uteri (CCU). 8th European Conference on Clinical Oncology and Cancer Nursing. 1995; 246.
46. Rowinsky EK, Donehower RC, Paclitaxel (taxol). N Engl J Med 1996; 332:1004.
47. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1.
48. Cortes JE, and Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643.
49. De Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54:4347.
50. Armand JP, and Cvitkovic E. Suramin: a new therapeutic concept. Eur J Cancer 1990 26:417.
51. Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin: active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993; 85:611.